Skip to content
Medical Health Aged Care, Seniors Interest

June 19 – 25 is Heart Failure Awareness Week – You’ve only got one heart. Don’t fail it.

hearts4heart 2 mins read

 

 

Media Alert

 

June 19 – 25 is Heart Failure Awareness Week

You’ve only got one heart. Don’t fail it.

 

Did you know . . .

 

  • Over 500,000 Australians are living with heart failure, with many more potentially undiagnosed.

 

  • The chronic condition claims the lives of 61,000 every year, and it’s the number one cause of hospitalisation in people over age 65.

 

  • As more people are surviving heart attacks and other acute heart diseases, more people are going to develop heart failure.

 

  • With early diagnosis, treatment and lifestyle changes, a person with heart failure can reduce their risk of hospitalisation, feel better, and live a longer and healthier life.

 

  • Despite the name, heart failure doesn’t mean the heart has stopped or failed, it means the heart is ‘failing’ to keep up with the body’s demands.

 

 

In the lead up to Heart Failure Awareness Week (June 19 - 25), peak body hearts4heart, the Parliamentary Friends of Heart and Stroke Foundations, cardiologists and heart failure patients and carers across the country are urging Australians to be smart about your heart and speak with your GP about heart failure if you’re over 65 or experiencing symptoms.

 

 

Arranging interviews

We can line up interviews with a hearts4heart spokesperson, medical expert, or case study.

 

 

Media Assets

We can assist you with a range of resources to help you build your story including content for TV, radio and online. 

 

 

 


About us:

About hearts4heart

Supported by Australian and New Zealand cardiologists, hearts4heart is a leading health promotion charity supporting, educating, and advocating for people living with heart disease.

 

For more information visit hearts4heart.org.au


Contact details:

Olivia Carolan 0414 440 788–/ [email protected]

Media

More from this category

  • Medical Health Aged Care
  • 08/12/2025
  • 10:11
BeOne Medicines Ltd.

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL Sonrotoclax in combination with BRUKINSA demonstrated rapid…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 09:40
Miltenyi Biomedicine

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease featuresA 12-day manufacturing time resulted in a vein-to-vein time of 14-16 days, reducing the likelihood for bridging therapy.BERGISCH GLADBACH, Germany, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Miltenyi Biomedicine today announced results from the pivotal DALY 2-EU trial evaluating the efficacy and safety of zamtocabtagene autoleucel (zamto-cel) compared with standard chemoimmunotherapy (R-GemOx or Pola-BR) in patients with…

  • Medical Health Aged Care, Seniors Interest
  • 08/12/2025
  • 08:56
Monash University

Men and women may need different medications to avoid broken bones

A new international study, published in Osteoporosis International and led by Monash’s Centre for Medicine Use and Safety (CMUS), investigated the risks of a…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.